arrow
V

Vianney Tricou

Takeda Pharmaceutical Company Ltd
H指数:21
被引数:2,834

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characterization of vaccine viremia, attenuation reversion, and safety: Combined results from the TAK-003 dengue vaccine clinical development program

疫苗病毒血症、减毒株回复和安全性表征:TAK-003登革热疫苗临床开发项目的综合结果

Vaccine
IF3.5
2026-07-012
OAAI
Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trial

对来自非登革热流行区的成人接种四价登革热疫苗(TAK-003)后的体液和细胞免疫反应:一项开放标签二期临床试验

Vaccine
IF3.5
2026-04-020
OAAI
Qdenga-induced dengue caused by minor DENV-2 subvariant(s) in the vaccine, with two amino acid substitutions in the E protein

Tricou, V.; Livengood, J.; Sharma, M.; Zent, O.; Rauscher, M.; Setoh, Y.X.; Brünner, C.; Biswal, S.; Kandeil, W. 关于:Pettersson等人. Qdenga诱导的登革热由疫苗中的次要DENV-2亚型(s)引起,并在E蛋白中有两个氨基酸替换。J. Travel Med. 2026, 33, taaf127. [Google Scholar] [CrossRef]

2026-01-010
PRE
Dengue virus infection reprograms baseline innate immune gene expression

登革病毒感染重编程基础固有免疫基因表达

Med
IF11.8
2025-09-080
OAAI
Operational challenges and lessons learned from conducting febrile surveillance in a long-term randomized dengue vaccine trial in Latin America and Asia-Pacific

在拉丁美洲和亚太地区开展长期随机登革热疫苗试验中的发热监测所面临的运营挑战与经验教训

2025-05-010
OAAI
Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America

亚洲太平洋和拉丁美洲地区参与DEN-301试验的儿童和青少年中,TAK-003对无症状登革热感染的预估疗效

2025-03-181
PRE
Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination
2024-04-294
OAAI
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003)
2021-10-04143
OAAI
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination
2020-12-1565
OAAI